We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s fourth-quarter 2017 earnings per American Depositary Receipt (ADR) remained flat year over year at $1.54.
Revenue: The company posted revenues of $4.5 billion in the reported quarter, up 9.6% including favorable currency movement. The Healthcare and Life Science segment drove the company’s organic growth.
Key Stats: The company has proposed a dividend of €1.25, increasing the payout by €0.05 maintaining the trend of rising dividend since 2009.
2018 Guidance: For 2018, the company expects its net sales to grow moderately. The company expects currency movements to have an unfavourable impact of 4% to 6% on EBIDTA.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Merck KGaA (MKGAF) Q4 Earnings Flat Y/Y, Sales Up
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s fourth-quarter 2017 earnings per American Depositary Receipt (ADR) remained flat year over year at $1.54.
Revenue: The company posted revenues of $4.5 billion in the reported quarter, up 9.6% including favorable currency movement. The Healthcare and Life Science segment drove the company’s organic growth.
Key Stats: The company has proposed a dividend of €1.25, increasing the payout by €0.05 maintaining the trend of rising dividend since 2009.
2018 Guidance: For 2018, the company expects its net sales to grow moderately. The company expects currency movements to have an unfavourable impact of 4% to 6% on EBIDTA.
Merck KGaA Price and EPS Surprise
Merck KGaA Price and EPS Surprise | Merck KGaA Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>